Fitch Ratings on Indian pharma companies: Indian pharmaceutical companies’ sales will grow robustly in the financial year ending March 2022 as sales normalise in categories affected by the pandemic in the previous year, says Fitch Ratings.
Sales of some of these products are still 10% below pre-pandemic levels, although they started to recover with the easing of curbs.
During the last 15 months, RattanIndia Power has repaid the debt of Rs.
Sentiments in the traders turned a little sceptical as former RBI Governor D Subbarao raised concerns about the country’s economic recovery being ” very uneven” and “sharpening inequities” between upper- and lower-income people.
The public offer of Shyam Metalics and Energy has received a 39 percent subscription on June 14, the first day of bidding.